# Brilinta DaYu Study

Study · id `cardio:ct-nct01870921` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01870921](<https://clinicaltrials.gov/study/NCT01870921>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01870921

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2004 participants.

## Technical summary

Registry record NCT01870921. Allocation not applicable; no masking; primary purpose treatment. Start 2013-06-26 (actual); primary completion 2015-09-30 (actual). Results posted on 2016-11-09.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2004 participants (enrolled count; ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Started: 2013-06-26 (actual) (ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Primary completion: 2015-09-30 (actual) (ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Completion: 2015-09-30 (actual) (ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Results first posted: 2016-11-09 (ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT01870921, source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01870921-2018-04-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Brilinta DaYu Study
- Acronym: DaYu
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Ticagrelor
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: c0eacab8a8eeb3994a537faa89b5f8b7c9d22fab280b06fd4087268e1d88eba1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
